The US Food and Drug Administration consequently approved empagliflozin for T2DM patients with established cardiovascular disease, and authoritative professional associations of diabetologists began recommending SGLT2 inhibition in their therapeutic guidelines for practitioners [3,4,5]. Here, SLC5A2 is linked to cardiovascular disorder.